Amphastar's 15min chart shows Bollinger Bands Narrowing, KDJ Death Cross, Bearish Marubozu.

Amphastar's 15-minute chart has exhibited several bearish technical indicators, including Bollinger Bands Narrowing, a KDJ Death Cross, and a Bearish Marubozu at 08/05/2025 15:15. This suggests that the magnitude of stock price fluctuations is decreasing, momentum is shifting towards the downside, and sellers are in control of the market. As a result, there is a strong likelihood that the bearish momentum will continue.

Amphastar Pharmaceuticals (AMPH) is set to release its Q2 2025 earnings results on August 6, 2025, with analysts expecting earnings of $0.71 per share and revenue of $173.42 million [1]. However, the company's 15-minute chart has exhibited several bearish technical indicators, including Bollinger Bands Narrowing, a KDJ Death Cross, and a Bearish Marubozu at 08/05/2025 15:15. These indicators suggest that the magnitude of stock price fluctuations is decreasing, momentum is shifting towards the downside, and sellers are in control of the market [2].

Analysts are generally cautious about Amphastar's prospects. Wells Fargo & Company recently reduced their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company [1]. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals, while JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price target [1]. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock, resulting in an average rating of "Hold" and a consensus target price of $32.33 [1].

Institutional investors have also shown interest in Amphastar Pharmaceuticals. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Intech Investment Management LLC, and AQR Capital Management LLC have recently increased their stakes in the company [1]. Despite these institutional holdings, the stock's performance has been mixed, with a 50-day simple moving average of $23.89 and a 200-day simple moving average of $27.04 [1].

The earnings report is expected to show a year-over-year decline in earnings on lower revenues, with earnings of $0.71 per share and revenue of $169.84 million [2]. The consensus EPS estimate has been revised 1.32% higher over the last 30 days, but the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -11.97% [2]. This suggests that analysts have become bearish on the company's earnings prospects.

Amphastar Pharmaceuticals' surprise history shows that the company has beaten consensus EPS estimates two times out of the last four quarters. However, the recent bearish technical indicators and analysts' cautious outlook suggest that the company may face challenges in the near term.

References:
[1] https://www.marketbeat.com/instant-alerts/amphastar-pharmaceuticals-amph-expected-to-announce-earnings-on-wednesday-2025-07-30/
[2] https://www.nasdaq.com/articles/analysts-estimate-amphastar-pharmaceuticals-amph-report-decline-earnings-what-look-out